FibroGen Inc. has reported its first quarter 2025 financial results, reflecting a significant decline in total revenue from continuing operations to $2.7 million, compared to $25.4 million recorded in the same period in 2024. The company also reported a net loss from continuing operations of $16.8 million, or $0.16 net loss per basic and diluted share, showing an improvement from the previous year's net loss of $49.0 million, or $0.49 net loss per share. As of March 31, 2025, FibroGen's cash, cash equivalents, and accounts receivable totaled $128.4 million, with $33.8 million reported in the U.S. The company announced that the anticipated sale of FibroGen China to AstraZeneca is expected to close in the third quarter of 2025, with a total consideration of approximately $185 million. This transaction is projected to extend the company's cash runway into the second half of 2027. In addition, FibroGen has filed a Type-C meeting request with the FDA for its drug roxadustat, aimed at addressing anemia associated with lower-risk myelodysplastic syndromes (LR-MDS), with feedback expected in the third quarter of 2025. The company is also planning to initiate a Phase 2 monotherapy trial of FG-3246 for metastatic castration-resistant prostate cancer in the third quarter of 2025, with topline results from a related study anticipated in the fourth quarter of 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.